Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results.
INTRODUCTION: Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction </= 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow-up in these higher-risk groups.
INTRODUCTION: Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction </= 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow-up in these higher-risk groups.
What the study was
- Study design
- Prospective Cohort Study
- Category
- Prevention
- Maturity
- Validated
- Journal
- Clin Cardiol
Why it surfaced
Matched watchlist topic(s): Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk. Study design: Prospective Cohort Study. Score 8/10. 🟢 Near-term implementable finding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.